Zenas BioPharma (Zenas) has been launched as a cross-border biopharmaceutical company committed to becoming a global leader in the development and delivery of immune-based therapies for patients in China and worldwide.
Zenas was founded and initially funded by Tellus BioVentures LLC (Tellus) and Fairmount Funds Management LLC (Fairmount) and is additionally backed by leading global life science investment funds including Quan Capital, WuXi Biologics Healthcare Ventures and Wellington Management.
According to a statement, Lonnie Moulder, Managing Member of Tellus and Founder of Zenas, serves as Executive Chairman and Interim Chief Executive Officer.
As a veteran life sciences founder and executive, he brings to Zenas a track record of success and the necessary skills to navigate the global biopharmaceutical landscape.
“We are excited about the launch of Zenas BioPharma and its pipeline of differentiated product candidates. These potentially best-in-class products are intended to bring innovation to patients with underserved diagnoses while also maximising value across the healthcare ecosystem,” said Moulder.
“The expanding Zenas leadership team and our network of business partners will drive operational excellence to deliver potentially transformative therapies to improve the lives of people living with autoimmune and rare diseases.”
Zenas debuts with a deep pipeline of seven innovative immune-based therapeutics that will continue to expand through a successful business development strategy. It owns worldwide rights to three of the seven pipeline programmes, which uniquely positions the Company to be global in scope.
Source: BERNAMA News Agency